Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) has a beta value of 2.06 and has seen 1.01 million shares traded in the last trading session. The company, currently valued at $17.50M, closed the last trade at $0.14 per share which meant 0.00% during that session. The CRBP stock price is -342.86% off its 52-week high price of $0.62 and 28.57% above the 52-week low of $0.10. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.46 million shares traded. The 3-month trading volume is 4.27 million shares.
The consensus among analysts is that Corbus Pharmaceuticals Holdings Inc. (CRBP) is an Overweight stock at the moment, with a recommendation rating of 2.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) trade information
The stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the CRBP stock price touched $0.14 or saw a rise of 6.67%. Year-to-date, Corbus Pharmaceuticals Holdings Inc. shares have moved 26.70%, while the 5-day performance has seen it change -3.31%. Over the past 30 days, the shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) have changed 26.93%. Short interest in the company has seen 3.9 million shares shorted with days to cover at 1.6.
Wall Street analysts have a consensus price target for the stock at $3.00, which means that the shares’ value could jump 95.33% from current levels. The projected low price target is $3.00 while the price target rests at a high of $3.00. In that case, then, we find that the current price level is -2042.86% off the targeted high while a plunge would see the stock gain -2042.86% from current levels.
Corbus Pharmaceuticals Holdings Inc. (CRBP) estimates and forecasts
Figures show that Corbus Pharmaceuticals Holdings Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -50.18% over the past 6 months, with this year growth rate of 27.03%, compared to 11.30% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are -150.00% and 37.50% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 5.30% over the past 5 years.
Corbus Pharmaceuticals Holdings Inc. is expected to release its next earnings report between March 06 and March 10 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)’s Major holders
Insiders own 0.48% of the company shares, while shares held by institutions stand at 24.67% with a share float percentage of 24.79%. Investors are also buoyed by the number of investors in a company, with Corbus Pharmaceuticals Holdings Inc. having a total of 78 institutions that hold shares in the company. The top two institutional holders are ETF Managers Group, LLC with over 7.06 million shares worth more than $1.78 million. As of Jun 29, 2022, ETF Managers Group, LLC held 5.64% of shares outstanding.
The other major institutional holder is Knoll Capital Management, LLC, with the holding of over 5.05 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $1.27 million and represent 4.03% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ETF Managers Tr-EFTMG Alternative Harvest ETF and Vanguard Total Stock Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 5.64% shares in the company for having 7.06 million shares of worth $1.78 million while later fund manager owns 2.43 million shares of worth $0.61 million as of Jun 29, 2022, which makes it owner of about 1.94% of company’s outstanding stock.